Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CTOR
CTOR logo

CTOR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Citius Oncology Inc (CTOR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.710
1 Day change
0.14%
52 Week Range
6.190
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CTOR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong bullish setup, has no supportive news or recent catalysts, no positive proprietary signal, and the technical trend is still bearish. Based on the current data, I would avoid buying now and prefer to stay out until momentum improves.

Technical Analysis

CTOR is trading at 0.6805, essentially flat versus the prior close of 0.6804, but the broader context is weak. Regular market change was -3.39% and pre-market change was -6.12%, showing recent selling pressure. Technicals are mixed to bearish: MACD histogram is positive and expanding, which is a small short-term improvement, but RSI_6 at 49.695 is neutral and does not confirm strength. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend remains downward. Pivot resistance is 0.683, with support at 0.624 and 0.588. The price is sitting just below pivot, so there is no clear breakout confirmation. The pattern-based trend estimate also looks weak, with a 60% chance of -0.72% next day and -2.5% next month.

Positive Catalysts

  • No news in the recent week. AI Stock Pick shows no signal on given stock today. SwingMax shows no signal on given stock recently. The only mildly positive technical factor is the MACD histogram being above zero and expanding, suggesting some short-term momentum improvement, but it is not strong enough to count as a buy catalyst.

Neutral/Negative Catalysts

  • No recent news catalysts, no positive options sentiment data, no AI Stock Picker signal, and no SwingMax signal. Hedge funds are neutral and insiders are neutral, so there is no evidence of strong accumulation. The stock also shows bearish moving averages and a weak near-term trend profile. No recent congress trading data is available, so there is no supportive political buying signal either.

Financial Performance

Financial snapshot data was not available due to an error, so there is no usable latest-quarter financial readout to support a buy decision. As a result, revenue and growth trends for the latest quarter season cannot be assessed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data was provided, so there is no visible recent trend in Wall Street upgrades, downgrades, or target changes. Based on the available information, the Wall Street view appears neutral to cautious rather than bullish.

Wall Street analysts forecast CTOR stock price to rise
Analyst Rating
0
Wall Street analysts forecast CTOR stock price to rise
Buy
Hold
Sell
0
Current: 0.709
sliders
Low
0
Averages
0
High
0
0
Current: 0.709
sliders
Low
0
Averages
0
High
0
Maxim
Michael Okunewitch
Hold
to
Buy
upgrade
$6
AI Analysis
2025-09-23
Reason
Maxim
Michael Okunewitch
Price Target
$6
AI Analysis
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim analyst Michael Okunewitch upgraded Citius Oncology to Buy from Hold with a $6 price target.
Maxim
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim upgraded Citius Oncology to Buy from Hold with a $6 price target. The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a \"key event\" for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could \"ramp quickly\" in 2026, the firm added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CTOR
Unlock Now

People Also Watch